ES2371479T3 - Uso de aimp2dx2 para el diagnóstico y tratamiento del cáncer. - Google Patents
Uso de aimp2dx2 para el diagnóstico y tratamiento del cáncer. Download PDFInfo
- Publication number
- ES2371479T3 ES2371479T3 ES05819055T ES05819055T ES2371479T3 ES 2371479 T3 ES2371479 T3 ES 2371479T3 ES 05819055 T ES05819055 T ES 05819055T ES 05819055 T ES05819055 T ES 05819055T ES 2371479 T3 ES2371479 T3 ES 2371479T3
- Authority
- ES
- Spain
- Prior art keywords
- aimp2
- aimp2dx2
- protein
- cancer
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20040097164 | 2004-11-24 | ||
| KR20040097164 | 2004-11-24 | ||
| KR1020050039073A KR20060057992A (ko) | 2004-11-24 | 2005-05-10 | p38-DX2 및 이의 용도 |
| KR20050039073 | 2005-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2371479T3 true ES2371479T3 (es) | 2012-01-03 |
Family
ID=37153221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05819055T Expired - Lifetime ES2371479T3 (es) | 2004-11-24 | 2005-11-18 | Uso de aimp2dx2 para el diagnóstico y tratamiento del cáncer. |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP4718556B2 (de) |
| KR (1) | KR20060057992A (de) |
| CN (1) | CN101087804B (de) |
| AT (1) | ATE521631T1 (de) |
| ES (1) | ES2371479T3 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9944713B2 (en) | 2004-11-24 | 2018-04-17 | Medicinal Bioconvergence Research Center | Antibody specific to the AIMP2-DX2 |
| CA2798139C (en) * | 2010-05-04 | 2019-09-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
| EP2945645B8 (de) * | 2013-01-17 | 2019-10-23 | Sylvain Tourel | Selektives zelltod-induzierendes binäres enzymsystem |
| KR102297505B1 (ko) * | 2016-03-07 | 2021-09-01 | 재단법인 의약바이오컨버젼스연구단 | Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법 |
| KR101831435B1 (ko) * | 2016-03-10 | 2018-02-22 | 재단법인 의약바이오컨버젼스연구단 | Aimp2-dx2 단백질에 특이적으로 결합하는 항체 |
| EP3375871A1 (de) | 2017-03-13 | 2018-09-19 | SIT Biotech GmbH | Enzymsystem zur auslösung von selektivem zelltod |
| US10716866B2 (en) | 2018-03-29 | 2020-07-21 | Generoath Co., Ltd | Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof |
| KR102248420B1 (ko) * | 2019-03-15 | 2021-05-06 | 주식회사 제너로스 | miR-142-3p의 표적 서열을 포함하는 재조합 벡터 |
| WO2022054999A1 (ko) * | 2020-09-14 | 2022-03-17 | 주식회사 제너로스 | 생착능이 증가된 줄기세포의 제조 방법 |
| US20240050527A1 (en) * | 2020-09-30 | 2024-02-15 | Generoath Co., Ltd. | METHODS OF TREATING AGE-RELATED MACULAR DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR miR-142 AND COMPOSITIONS THEREOF |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100575251B1 (ko) * | 2003-03-03 | 2006-05-02 | 재단법인서울대학교산학협력재단 | p38/JTV-1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법 |
-
2005
- 2005-05-10 KR KR1020050039073A patent/KR20060057992A/ko active Pending
- 2005-11-18 JP JP2007542907A patent/JP4718556B2/ja not_active Expired - Fee Related
- 2005-11-18 AT AT05819055T patent/ATE521631T1/de not_active IP Right Cessation
- 2005-11-18 ES ES05819055T patent/ES2371479T3/es not_active Expired - Lifetime
- 2005-11-18 CN CN2005800378029A patent/CN101087804B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008521398A (ja) | 2008-06-26 |
| CN101087804A (zh) | 2007-12-12 |
| ATE521631T1 (de) | 2011-09-15 |
| JP4718556B2 (ja) | 2011-07-06 |
| CN101087804B (zh) | 2012-07-04 |
| KR20060057992A (ko) | 2006-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1814909B1 (de) | Verwendung von aimp2dx2 zur diagnose und behandlung von krebs | |
| US8003780B2 (en) | AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2 | |
| US6689744B2 (en) | Notch receptor agonists and uses | |
| US8809291B2 (en) | Id-1 gene and gene products as therapeutic targets for treatment of breast cancer and other types of carcinoma | |
| US5654406A (en) | Antibody to ERBB2 promoter binding factor | |
| JP2005521418A (ja) | ヒト・リボヌクレオチド還元酵素m2サブユニット | |
| JP5836940B2 (ja) | ソリシジン由来ペプチドならびにtrpv−6がんの検出および薬剤送達のための方法 | |
| CN101087804B (zh) | 用于诊断和治疗癌症的aimp2dx2的用途 | |
| JP4365583B2 (ja) | ノッチレセプターアゴニスト及び用途 | |
| JP2008513462A (ja) | p53−依存性および非依存性ガン抑制の調節因子としてのARF−BP1、およびその使用 | |
| AU2001292750A1 (en) | Notch receptor agonists and uses | |
| TW200831898A (en) | Treatment of insulin resistance | |
| US20100166652A1 (en) | Laminin receptor 1 precursor protein (37LRP) epitope delineated by an hepatocellular carcinoma specific antibody | |
| ES2805206T3 (es) | Enfoque dirigido a GDF6 y a señalización de BMP para la terapia contra el melanoma | |
| KR20070113926A (ko) | 암의 진단과 치료를 위한 aimp2dx2의 용도 | |
| US10023915B2 (en) | Method for screening for a cancer treatment agent using the interaction between PAUF and a binding partner thereof | |
| JP2008169132A (ja) | Lin7cの癌の転移診断への応用 |